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HER2/neuFalse-positive results in diagnostic immunopathology can lead to unnecessary treatments. The purpose of this
study was to do a side-by-side comparison of 10 different antibodies commonly used in the clinical laboratory
altering only the horseradish peroxidase (HRP) conjugate. The automated Leica BOND-MAX platform was used
to study serial sections from 203 tissues including controls compared in a blinded fashion using the HRP
conjugates from Leica (ReﬁneHRP), VentanaMedical Systems (UltraviewHRP), and Enzo Life Sciences (Polyview
HRP). False-positive results, deﬁned as signal from cases known to not contain the target, were noted in 23 (13%)
of 171 cases with the Leica HRP, 62 (36%) of 171 cases with the Ventana HRP, and no cases with the Enzo
HRP. Each data set was performed simultaneously allocating 1 tray for each of the 3 different HRP conjugates.
HER2/neu analysis from triple-negative breast cancers were scored as positive by immunohistochemistry in 6
(24%) of 25 cases using either the Reﬁne or Ultraview HRP and in 0 of 25 cases with the Enzo conjugate.
It is concluded that false-positive results in a wide spectrum of diagnostic immunopathology tests can occur
from 13% to 36% of cases with commonly used commercial assays based on the HRP conjugate.
© 2016 The Author. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Perhaps the most substantial advance in the ﬁeld of diagnostic
surgical pathology over the last 25 years has been the predominance
of immunohistochemistry in making deﬁnitive diagnoses and treat-
ment decisions [1-8]. This advance, in turn, is strongly related to the
improvements in generating antigen-speciﬁc antibodies, in under-
standing the role of speciﬁc proteins in many different diseases, and in
the automation of the assay allowing much higher throughput. To cite
a few examples, the diagnosis of the mesothelioma as well as the site
of metastatic disease of unknown primary has been revolutionized by
immunohistochemistry [1,3,5,7,8]. Plaza et al [7]were able to character-
ize 118 tumors to soft tissues as metastatic and not primary sarcomas
based on the immunohistochemistry proﬁle. The clinical signiﬁcance
of immunohistochemistry results is underscored by studies showing
that breast cancers that are HER2/neu positive and treated with
herceptin and docetaxol will have an overall response rate of 61% as
comparedwith 34% if the latter drug alone is used [4]. Still, it iswell doc-
umented that herceptin can cause serious adverse effects including
heart damage in up to 30% of patients and pulmonary edema, andy a grant from the Alzheimer's
This is an open access article under tthus, it is important that only women with HER2/neu ampliﬁed breast
cancers receive the treatment [4].
False-positive and false-negative results in immunohistochemistry
have been recognized since the methodology began [9-13]. Even a
few years ago, it was reported that about 20% of ER and PR immunohis-
tochemistry results for breast cancer in the diagnostic laboratory were
inaccurate [11]. It is well documented that variables such as type and
pH of the ﬁxative, time of ﬁxation, and time interval after tissue pro-
curement before ﬁxation can be correlated with either poor signal
(false negative) or high background (false positive) [9,13]. These issues
have been mitigated by the near universal use of rapid ﬁxation in 10%
buffered formalin for small surgical biopsies. However, other variables
such as the pretreatment conditions (protease vs antigen retrieval), tissue
quenching, antibody concentration, incubation time of the primary anti-
body, and the detection kit can also correlate with both false-negative
and false-positive results [9,13-15]. The most commonly used catalytic
enzyme in diagnostic immunohistochemistry is horseradish peroxidase
(HRP). Thus, ultimately, false-positive results reﬂect the inappropriate
activity of the peroxidase in cells that do not contain the antigen of interest.
There are many commercially available kits and automated plat-
forms used in diagnostic immunohistochemistry. Two of the most
widely used are from Leica Biosystems and Ventana Medical Systems.
The purpose of this articlewas to compare the secondaryHRP conjugate
from Leica, Buffalo Grove, IL, Ventana, Tuscon, AZ, and Enzo Life
Sciences, Farmingdale, NY in a side-by-side comparison on the Leica
BOND-MAX.he CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.1. Case selection
Each sample was from a surgical biopsy ranging in size from 5 to
20 mm that was ﬁxed immediately after excision in 10% neutral-
buffered formalin for 7 to 24 hours, then embedded into parafﬁn.
When indicated, 5-mm cores of the larger biopsieswere prepared as tis-
suemicroarrays. For each tissue, the histologic diagnosis was conﬁrmed
using hematoxylin and eosin (H&E) staining. The pathology reports,
including all immunohistochemistry and ancillary tests, were reviewed
to conﬁrm the diagnosis.
The study focused on the following commonly encountered
diagnostic decisions: melanoma vs nevus, cervical intraepithelial
neoplasia (CIN) vs a benignmimic of CIN, leiomyoma vs leiomyosarcoma,
small cell carcinoma of the lung vs non–small cell cancer, and the
ER/PR/HER2/neu status of breast carcinomas.2.2. Diagnostic criteria of false-positive and false-negative results
plus signal
Extensive clinical-pathologic diagnoses were available for each case,
and pathology reports were reviewed to conﬁrm the diagnosis. In this
manner, false positives for individual cases were determined by the
presence of a 3,3′-diaminobenzidine (DAB) precipitate in cells known
to not have the target of interest. For example, a triple-negative breast
cancer casewas scored as a false-positive result for HE2/neu if complete
membrane staining was observed in more than 10% of the tumor cells.
Similarly, if a breast cancer case was known to be HER2/neu ampliﬁed,
then the HER2/neu test was scored as a false negative if less than 10%
of the tumor cells showed complete membrane staining.
We also determined false-positive rates for groups of tissues by
using as a reference point the published results for the expression of a
given protein. For example, a cutoff value of 3.6 for the Ki-67 index
has been shown to differentiate uterine leiomyoma vs leiomyosarcoma
[16]. Similarly, the Ki-67 index formesothelial derived inclusion ovarian
cysts is very low (b0.1) [17].2.3. Immunohistochemistry protocol
Each antibody (either mouse or rabbit) was optimized with known
positive controls using a previously published protocol [13,14].
The following antibodies were used in this study: HMB45 (RTU, Enzo),
chromogranin (RTU BioGenex), melanin-A, S-100, HER2/neu, ER, Ki-67
(each RTU, Ventana), and p16 (RTU CINtec), Ki-67 (Dako, 1:200), and
HER2/neu (1:1500, Dako). For each antibody, optimal pretreatment
consisted of antigen retrieval for 30 minutes using the Leica AR #2
solution, except for HER2/neu where 10 minutes of pretreatment in
this solution was optimal.
The incubation time for the primary antibody was 60 minutes.
The incubation time for the HRP conjugates was 13 minutes, and
DAB incubation time was 10 minutes. A given experimental set
consisted of 3 serial sections in the 3 separate trays of the Leica
BOND-MAX, where the protocols were identical except for the
HRP conjugate source. In this manner, variables such as the
primary antibody, lot number for the detection kit, and antigen
retrieval solution/time were identical for the slides tested for the
Enzo, Ventana, and Leica HRPs. The HRP polymer from Leica was
from the Bond Polymer Reﬁne Detection system (catalogue #DS
9800). The Ventana HRP came from the UltraView Universal DAB
detection kit (catalogue #760-500). The Enzo HRP polymers were
the antirabbit (PolyView Plus HRP—catalogue #ENZ-ACC 103-
0150) and the antimouse conjugates (catalogue #ENZ-ACC 104-
0150).2.4. Quantiﬁcation of the data
Each immunohistochemistry result was scored blinded to the source
of the HRP conjugate. The coding included the diagnosis of each case
and the primary antibody. In this way, it could be determined which
cell type(s) should show a signal, the speciﬁc cell localization of the
signal (cytoplasmic, cell membrane, or nuclear), and which cell(s) would
not contain the target of interest. A case was scored as a false negative if
less than 10% of the target cells showed a signal. A case was scored as a
false positive if more than 10% of nontarget cells showed a signal. The
Ki-67 index was obtained by scoring at least 250 target cells.
2.5. Statistical analyses
Statistical analysis was done using the InStat Statistical Analysis Software
(GraphPad Software, La Jolla, CA) (version 3.36) and a paired t test (also
referred to as a “repeated-measure t test”) testing the null hypothesis
that the probability that the false-positive rate for a given HRP conju-
gate was equivalent to the probability with a different conjugate. The
null hypothesis was rejected if the signiﬁcance level was less than 5%.
3. Results
3.1. Human papillomavirus–positive CIN 1 lesions vs
human papillomavirus–negative mimics of CIN
The study began comparing CIN 1 lesions to mimics of CIN. It is well
documented that CIN 1 represents productive infection by human
papillomavirus (HPV). Thus, these lesions contain high copy of HPV
DNA that is easily detected by in situ hybridization [13]. Although the
histologic changes induced by the virus that include disorganized squa-
mous cell growth, variability in nuclear size, shape, and chromaticity,
and variable-sized perinuclear halos may be diagnostic, other non-
HPV conditions such as reactive squamous metaplasia can mimic
the disease [13].
Mimics of CIN upon cervical biopsy for an atypical Papanikolaou test
can occur in up to 30% of such biopsies. Most diagnostic pathology
laboratories use p16 and Ki-67 immunohistochemistry testing to
differentiate CINs from their mimics [13,18]. Thus, we studied 28 cervi-
cal biopsies in which 14 were determined to be CIN 1 by H&E examina-
tion and a positive HPV DNA in situ result. The other 14 cases were
equivocal on H&E examination and were HPV DNA negative and, thus,
were determined to be mimics of CIN (Fig. 1).
Each of these 28 tissueswas tested for p16 and Ki-67 using the 3 differ-
ent HRP conjugates. The results are summarized in Table 1. Note that each
of the CIN 1 lesionswas strongly positive for p16 andKi-67with each of the
3HRPconjugates.Alsonote that themimics of CIN1were scoredaspositive
for both p16 and Ki-67 in 4, and 7 of 14 cases using the Enzo, Leica, and
Ventana HRP conjugate, respectively. Representative data are presented in
Fig. 1. Thus, although false-negative results were not evident, false-
positive resultswere evident in29%and50%of thenegative for CINbiopsies
using the Leica and Ventana HRP conjugate, respectively.
3.2. Breast carcinomas: ER, PR, and HER2/neu status.
Next a series of breast carcinomas were studied. These included 50
breast cancers where the ER/PR status had already been determined.
These 50 cases included 25 triple-negative (ER, PR, HER2/neu negative)
breast cancers and 25 tubular carcinomas (or well-differentiated breast
cancers with tubular features) where each tumor, as expected, was
strongly ER+/PR+ and HER2/neu negative. Ten breast cancers docu-
mented to be HER2/neu ampliﬁed by ﬂuorescence in situ hybridization
served as the positive control for this immunohistochemistry test.
The Enzo, Leica, and Ventana HRP conjugate correctly identiﬁed the
10 HER2/neu-positive breast cancers as ampliﬁed for this oncogene
(Fig. 2). Table 2 contains a summary of the data for the 50 cases. Note
Fig. 1. Ki-67 and p16 analyses in a mimic of CIN. (A) The strong signal after in situ hybridization for HPV DNA typical of a CIN 1 lesion. (B) Note the absence of a signal after HPV in situ
hybridization in a mimic of a CIN 1 lesion from a woman with an Atypical squamous cells of undetermined signiﬁcance Papanikolaou test. This lesion was negative for p16 using the
Enzo HRP conjugate (C) and showed a cytoplasmic signal in most of the squamous cells for p16 using the Leica (D) and Ventana (E) HRP conjugates. Note in the latter 2 images a
signal in the benign endocervical cells (arrow) that would not be expected to contain HPV. (F) The Ki-67 stain using the Enzo HRP showed only a basal cell signal as expected for
benign squamous epithelia. However, for each the Leica (G) and Ventana (G) HRPs, the Ki-67 signal is evident in cells above the basal epithelia which fulﬁlls the scoring criteria for a CIN.
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breast cancers as ER+. The false-positive rate for HER2/neu in the
tubular carcinomas, deﬁned by at least 10% of the cancer cells showing
a complete cell membrane signal in HER2/neu nonampliﬁed cases,
was 0%, 24%, and 32% of cases with the Enzo, Leica, and Ventana HRP,
respectively. Similar results were obtained when either the Ventana or
DakoHER2/neu primary antibodywasused. Also note that a nuclear sig-
nal for ER in more than 5% of the tumor cells were evident in 0%, 12%,
and 24% in the ER-negative cases using the Enzo, Leica, and Ventana
HRP, respectively. Fig. 2 shows representative examples for ER stainingin a triple-negative breast cancer. Note that both the Leica and Ventana
HRP show a nuclear based signal not only in cancer cells but in scattered
mononuclear cells, which is another indicator of a false-positive result.
3.3. Leiomyoma vs leiomyosarcoma of the uterus
Leiomyomas of the uterus are common tumors and often show ei-
ther hypercellularity or focal atypia that raises thequestion ofmalignant
transformation. Hence, it is common for the gynecologic pathologist
to have to differentiate cellular, atypical, or so-called bizarre
Table 1
Detection of HPV DNA, p16, and Ki-67 in cervical biopsies
Category p16+ Ki-67+ Combined p16/Ki-67 score
CIN 1
Enzo HRP 14/14 14/14 14/14
Leica HRP 14/14 14/14 14/14
Ventana HRP 14/14 14/14 14/14
Mimic of CIN
Enzo HRP 0/14 0/14 0/14 (0%)
Leica HRP 9/14 4/14 4/14 (29%)a
Ventana HRP 12/14 7/14 7/14 (50%)a
a The percentages of false-positive results from the combined scores using the Leica and
Ventana HRPs are signiﬁcantly greater than that for the Enzo HRP for the mimics of CIN 1
(P b .001).
Table 2
Detection of ER and HER2/neu by immunohistochemistry in breast cancers
Category ER+ HER2/neu+
Tubular carcinomas
Enzo HRP 25/25 0/25
Leica HRP 25/25 6/25 (24%)a
Ventana HRP 25/25 8/25 (32%)a
Triple-negative cancer
Enzo HRP 0/25 0/25
Leica HRP 3/25 (12%) 6/25 (24%)a
Ventana HRP 6/25 (24%)a 6/25 (24%)a
a The data from the HER2/neu and ER scores using the Leica and Ventana HRPs are
signiﬁcantly greater than that for the Enzo HRP in the cases known to be negative for
HER2/neu and ER, respectively (P b .001 for each ER and HER2/neu).
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this differentiation was done using a mitotic index. Now, the Ki-67
index determined by immunohistochemistry is the method of
choice as it is more objective [16]. It has been documented that a
Ki-67 index less than 3.6 is indicative of a benign leiomyoma,
whereas if the index is above that score, then the lesion is most likely
malignant [16]. Unequivocal uterine leiomyosarcomas may have Ki-67
indexes greater than 20.
Three leiomyosarcomas were studied and each HRP conjugate
yielded a Ki-67 index greater than 10 for each lesion (data not
shown). A tissue microarray that included 52 uterine leiomyomas that
were diagnosed on both pathologic and clinical grounds was examined
in a blinded fashion for Ki-67 using the 3 different commercially avail-
able conjugates. These data are presented in Table 3. The Enzo and
Leica HRP conjugates correctly identiﬁed each of the 52 leiomyoma as
having a Ki-67 index less than 3.6 with mean indexes of 0.4 and 1.1,
respectively. Note themuch greatermean Ki-67 indexwith the Ventana
HRP. Representative data are presented in Fig. 3. Similar results were
noted when the Ki-67 primary antibody from Dako and Ventana was
compared for the 3 HRP conjugates (data not shown).
Ovarian mesothelial inclusion cysts are commonly seen in the
pathology laboratory. Such lesions are usually slow growing and, thus,
have a very low Ki-67 index [17]. Thus, we also determined the Ki-67
index for 20mesothelial inclusion cysts using the 3 different HRP conju-
gates. The Ki-67 indexes were 0.1, 0.1, and 7.6 for the Enzo, Leica, and
Ventana HRP conjugates, respectively, where the latter value is much
greater than the published Ki-67 index for such tissues [17].Fig. 2.HER2/neu and ER expression in breast cancers. (A) The strong cell membrane–based signal for HER2/neu with the Enzo HRP conjugate in a positive control tissue. (B and C) Seria
sections analyzed for HER2/neu protein using either the Leica or Ventana HRP conjugate, respectively. Note that each shows both a cell membrane and cytoplasmic signal. (D) A negative
ER result in a triple-negative breast cancer using the Enzo HRP. The insert is the positive result for the adjacent benign breast tissue that serves as an internal positive control
Serial sections using the Leica (E) and Ventana (F) HRP conjugates show both a nuclear signal in the cancer cells (arrowhead) and a signal in mononuclear cells (large arrow)
each indicative of a false-positive result.3.4. Melanoma vs nevus
Next the category of melanoma vs nevus was studied. An
immunohistochemistry-based scoring system has gained favor for this
common problem in the diagnostic anatomic pathology laboratory. It
is based on a sum of the scores from the Ki-67 index (0-4), p16 (0-3),
and HBM45 (0-2) immunohistochemical analyses [19]. A combined
value of 0 to 3 strongly favors a benign lesion, whereas a score of 4 to
9 is highly consistent with melanoma [19].
Twenty melanocytic lesions were studied (8 melanomas and 12
nevi). In each of the 20 cases, the Enzo HRP–derived scores were 0 to
3 for the nevi and 4 or higher for themelanomas. The Leica HRP yielded
a score of 3 for one melanoma due to strong p16 and HMB45 staining;
each nevus was scored as 0 to 3. As a reﬂection of the stronger p16
and HMB45 staining with the Leica HRP, it gave lower overall scores
for the p16 test in the melanomas (average, 1.1 vs 2.7 for the Enzo
HRP) as well as lower HMB45 scores for the melanomas (average, 1.0
vs 1.4 for the Enzo HRP). The Ventana HRP gave scores greater than
4 for each melanoma, but did give scores of 4 (1 case) and 5 (2 cases)
for 3 of 12 nevi owing to higher relative scores for the Ki-67 test (data
not shown).
3.5. Lung cancers and metastatic melanomas vs thyroid cancers
In the last grouping, 10 lung cancers (5 small cell and 5 non–small cell)
and10metastatic tumors in lymphnodes (5melanomas and5 thyroid can-











Uterine leiomyoma, mean (SD) 0.4 (0.2) 1.1 (0.3) 8.8 (6.1)a
Cases that had Ki-67 index N3.6 0/52 0/52 26/52
a The data from the Ki-67 score using the Ventana HRP are signiﬁcantly greater than
that for the Leica and Enzo HRPs (P b .001).
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identiﬁed the 5 small cell cancers with the 3 different HRP conjugates.
However, the chromogranin test was positive in 2 of 5 non–small cell
cancers with the Leica and Ventana HRPs, but not the Enzo HRP (data
not shown).
False-positive results were seen with the HMB45 immunohisto-
chemistry test in 2 and 3 of 5 cases of metastatic thyroid cancer with
the Leica and Ventana HRP conjugates, respectively; no such back-
groundwas seenwith the Enzo HRP (Fig. 4). Themetastatic melanomas
were scored as false positives if a signal was seen in eithermononuclear
and/or endothelial cells. The Enzo HRP showed a signal for themelan-A
and HMB45 antibodies that localized to only the melanoma cells. In 2
and 4 of 5 cases, respectively, a signal was seen in either mononuclear
or endothelial cells as well as the melanoma cells with the Leica
and Ventana HRP conjugate, respectively, indicative of a false-positive
result (Fig. 4).
4. Discussion
Themain ﬁnding in this study is that a variable usually not associated
with false-positive results, the HRP conjugate, can be strongly related to
background in diagnostic immunohistochemistry. This study focused on
testing routinely done in the diagnostic immunopathology laboratory. It
was documented that 2 commercially available kits (Leica DAB Reﬁne
assay and the Ventana Ultraview kit) may overdiagnose, for example,
CIN lesions, leiomyosarcomas, and the HER2/neu/ER status of a given
breast cancer. Because the exact contents of these HRP conjugates isFig. 3. Ki-67 staining in leiomyomas. The lesion was a leiomyoma from a 20-year-old woman th
Enzo (A) and Leica (B) HRP conjugates were each negative. However, many tumor cells showe
panel D). The Ki-67 index for the lesion with the latter conjugate was greater than 4 and, thusproprietary, one cannot say for certain why the Leica and Ventana HRP
polymers were more susceptible to background. The false-positive
results were not eliminated by doing a prolonged hydrogen peroxide
block or diluting the conjugates 1:1 (GJ Nuovo, unpublished data).
One may speculate that the concentrations of the HRP conjugate may
be much higher in the Leica and Ventana preparations as a means to
insure the strongest possible signal; indeed, no false-negative results
were seen. Another possibility not mutually exclusive is that the Enzo
HRP conjugate preparation includes other reagents that inhibit its non-
speciﬁc binding to cells that do not contain the epitope of interest.
Not surprisingly, the false-positive results were also evident in im-
munohistochemistry done for research. For example, proteins rarely
found in normal brain (hyperphosphorylated tau protein and MCL1)
were detected in such tissues with the Leica and Ventana HRPs but
not the Enzo conjugate (GJ Nuovo, unpublished observation). Also,
a diffuse brown “blush,” though not background as it did not localize
to speciﬁc cell types, was much less common with the Enzo HRP
conjugate compared with the other 2 products when examining serial
sections in the brain sections.
The recognition of a false-positive result by a surgical pathologist de-
pends to some degree on the person's expertise. An expert in gyneco-
logic pathology, for example, would likely not report a false-positive
p16 and/or Ki-67 result for a cervical biopsy if he/she was certain that
theH&E ﬁndings could not represent CIN. For cervical biopsies, the diag-
nostic surgical pathologist has another more objective test, the HPV
DNA in situ test, that when negative would strongly raise into doubt a
diagnosis of CIN which is important given that it is a sexually transmit-
ted disease [13]. Similarly, diagnostic pathologists are trained to not
score HER2/neu immunohistochemistry test results as positive if the
signal is mostly cytoplasmic. However, a disconcerting observation in
this study was that in some of the false-positive cases, the staining
was in the correct cell type and subcellular compartment. This was evi-
dent in the false-positive ER and Ki-67 cases. The latter was clearly evi-
dent in the leiomyomas where Ki-67 indexes of greater than 4,
consistent with a leiomyosarcoma, were commonly seen in lesions
that based on the histology examination and clinical follow-up were
clearly benign.at was well deﬁned and though cellular did not show any necrosis. The Ki-67 test with the
d a nuclear signal using the Ventana HRP conjugate (panel C and at higher magniﬁcation,
, suggestive of a malignant tumor.
Fig. 4.HMB45 analyses in metastatic thyroid cancer andmelanoma. (A-C) Serial sections of a papillary thyroid cancer metastatic to a regional lymph node analyzed for HMB45. Note the
lack of a signal with the Enzo HRP conjugate (A) and the false-positive signals in the tumor cells when using either the Leica (B) or Ventana (C) HRP conjugates. In comparison, HMB45
testingwas done during the same experimental run for amelanomametastatic to a lymph node. (D) Note that the signal is conﬁned to the tumor cells using theHRP conjugate from Enzo.
A strong signal is evident with the Leica (E) and Ventana (F) HRPs in the serial sections, but background staining in the adjacent small blood vessels (arrow) is also evident.
59G. Nuovo / Annals of Diagnostic Pathology 25 (2016) 54–59The automated systems from Leica and Ventana and associated kits
each are relatively “open systems” that allow one to substitute other re-
agents. This is the reason that in this study, a direct comparison of the
Leica, Enzo, and Ventana HRP antirabbit/antimouse conjugates could
be done as one only had to add 2 “open canisters” that included the
Enzo and Ventana HRPs and program themachine to use 1 of the 3 con-
jugates per tray. Thus, all the other reagents/conditions of a given exper-
imental runwere identical. This alsowouldallowadiagnostic pathologist to
use the HRP conjugate of their choice in the diagnostic laboratory.
Clearly, many variables can cause both false-negative and false-
positive results in the diagnostic immunopathology laboratory
[9,13,15]. In my personal experience, the 2 most common variables for
false-positive results with immunohistochemistry are incorrect
pretreatment and too concentrated a primary antibody. This study
adds another potential cause for false-positive results, the HRP
conjugate, as well as reminding us the importance of interpreting the
immunohistochemistry data in the context of the H&E ﬁndings and
the clinical information.
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